- Posted by dextera
- On June 16, 2016
Chief Operating Officer
Mr. Palermo joined Dextera Surgical in November 2015 with close to 30 years of medical device development and management expertise. Most recently, he served as acting CEO of UlceRx Medical, a start-up chronic wound care company. Prior to UlceRx, Mr. Palermo was president and CEO of ReVascular Therapeutics (acquired by Boston Scientific in 2011), where he revamped the technology platform to meet market demand for the TruePath CTO Device system. Prior to ReVascular Therapeutics, Mr. Palermo served as vice president of operations and engineering at Ensure Medical where he was responsible for regulatory, clinical, quality assurance, research and development and operations for the development of the ExoSeal bio-absorbable femoral closure device. Prior to Ensure Medical he served in a variety of escalating roles related to engineering, operations, research and development and business development at a variety of medical device companies.
Mr. Palermo received a bachelor’s degree in technical management from New Hampshire College and holds more than 40 issued and pending patents.